Compare Medpace Holdings Inc (MEDP) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Noble Corporation plc — how do they compare? Medpace Holdings Inc trades at $616.5 (market cap $16.82B), while Noble Corporation plc trades at $42.56 (market cap $6.73B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.74% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Noble Corporation plc for 26 Days on average.
| MEDP | NE | |
|---|---|---|
Market Cap | $16.82B | $6.73B |
Volume | 223,093 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $630.19 | $54.37 |
52-Week Low | $393.42 | $26.70 |
Typical Hold Time | 14 Days | 26 Days |
Enterprise Value | $16.44B | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Noble Corporation (NE) trades at $42.21, up 3.03% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income dropping from $217M to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though earnings have been inconsistent with two misses and one beat in the last four quarters.
The stock presents a cautious opportunity with analyst consensus target of $52.00 offering 23% upside, but faces headwinds from declining profitability and ongoing SEC investigation. Investors should weigh the contract wins against execution risks and margin pressure in the offshore drilling sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
